assessing

Newest first, then by address. Each study has a usefulness score out of 100 (rubric version 4.0); tap a score to see what makes it up. Tags were assigned automatically from each study's title and summary. The same studies as a filter in the library.

1. 76/100

   Potential utility of plasma pTau217 for assessing amyloid and tau biomarker profiles

   ✓ Peer-reviewed alzhub usefulness score 76 out of 100. European journal of nuclear medicine and molecular imaging · 2025-08-06 · Biomarkers

   Plasma pTau217 is effective for predicting A/T biomarker profile and cognitive decline, though further study is needed to better explain its association with Aβ and tau PET staging.

   • Biomarkers
   • Diagnosis
2. 52/100

   Assessing diagnostic performance of plasma biomarkers in Alzheimer's disease versus cognitively unimpaired individuals: P-tau217 emerges as the optimal marker in Chinese cohorts

   ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Frontiers in aging neuroscience · 2025-03-26 · Biomarkers

   P-tau217 stands out as a highly effective biomarker for distinguishing AD from CUC, exhibiting extensive clinical application potential in the Chinese population.

   • Biomarkers
   • Diagnosis
3. 52/100

   Clinical value of plasma ALZpath pTau217 immunoassay for assessing mild cognitive impairment

   ✓ Peer-reviewed alzhub usefulness score 52 out of 100. Journal of neurology, neurosurgery, and psychiatry · 2024-10-16 · Biomarkers

   Plasma pTau217 and pTau181 both correlate with AD, but the fold change in pTau217 makes it better to diagnose cerebral amyloidosis, and predict cognitive decline and conversion to AD dementia.

   • Biomarkers
   • Early Stage
4. 91/100

   Assessing the causal role of epigenetic clocks in the development of multiple cancers: a Mendelian randomization study

   ✓ Peer-reviewed alzhub usefulness score 91 out of 100. eLife · 2022-03-29 · Genetics

   Meta-analysed IVW MR findings suggested that higher GrimAge acceleration increased the risk of colorectal cancer (OR = 1.12 per year increase in GrimAge acceleration, 95% CI 1.04-1.20, p = 0.002).

   • Genetics
5. 43/100

   Is Korea Prepared for an Alzheimer's Disease-Modifying Therapy? Assessing the Korean Healthcare System Infrastructure and the Effect of Blood-Based Biomarker Tests

   ✓ Peer-reviewed alzhub usefulness score 43 out of 100. Annals of geriatric medicine and research · 2021-02-04 · Biomarkers

   South Korea's healthcare infrastructure requires more preparation for the introduction of a disease-modifying therapy, with the primary capacity limitation being the low number of dementia specialists.

   • Biomarkers
   • Treatments
6. 55/100

   A comprehensive analysis of methods for assessing polygenic burden on Alzheimer's disease pathology and risk beyond APOE

   ✓ Peer-reviewed alzhub usefulness score 55 out of 100. Brain communications · 2019-12-16 · Genetics

   Genome-wide association studies have identified dozens of loci that alter the risk to develop Alzheimer's disease.

   • Genetics

All topic tags with their study counts